PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $20,406 | $9,560 | $48,958 | $151,493 |
| - Cash | $10,474 | $38,789 | $33,699 | $44,446 |
| + Debt | $10,917 | $13,567 | $25,375 | $27,448 |
| Enterprise Value | $20,849 | -$15,662 | $40,634 | $134,495 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1,608 | -$2,908 | -$5,377 | -$4,991 |
| % Margin | – | – | – | – |
| EBITDA | -$22,930 | -$3,460 | -$47,825 | -$66,382 |
| % Margin | – | – | – | – |
| Net Income | -$23,488 | -$227 | -$53,797 | -$73,300 |
| % Margin | – | – | – | – |
| EPS Diluted | -4.62 | -0.1 | -22.7 | -36.55 |
| % Growth | -4,520% | 99.6% | 37.9% | – |
| Operating Cash Flow | -$24,367 | -$31,764 | -$56,770 | -$51,720 |
| Capital Expenditures | -$217 | -$85 | -$298 | -$1,141 |
| Free Cash Flow | -$24,584 | -$31,849 | -$57,068 | -$52,861 |